OptiBiotix
Health
plc
("OptiBiotix"
or the "Company")
Launch of Daily Nouri FeelFull product in
America
SlimBiome® containing finished products
OptiBiotix Health plc
(AIM: OPTI), a life
sciences business developing compounds to tackle obesity, high
cholesterol,
diabetes and
skincare, announces the launch of FeelFull, containing
SlimBiome®, by Daily Nouri ("Nouri") in the United States of
America (USA).
Daily Nouri is a well-known brand in
the USA known for its science-backed, clinically supported
probiotic and prebiotic solutions which impact on gut
health. Nouri sell their products in their
online store (www.dailynouri.com),
on Amazon, and in stores of some of the largest
retailers in the USA such as Walmart and
Albertsons.
FeelFull is a prebiotic lemonade
drink containing SlimBiome® formulated by
Nouri which has been created "to
help consumers regulate appetite, curb cravings, and support
metabolic health by increasing viscosity in the stomach, slowing
gastric emptying, and stabilising blood sugar levels to create a
feeling of fullness and help satiate overall desire for food
intake.". The lemonade is a powdered
drink in portable stick packs which can be mixed with water with
'on pack' health claims which state daily use supports 'reduced
appetite and cravings' and a 'feeling of fullness' derived from
OptiBiotix's multiple clinical studies. 'On pack' health claims are
important in differentiating products in the weight management
market and are an area of high consumer interest since the launch
of the appetite reducing anti-obesity drugs. Nouri forecast a
requirement for ten metric tons of SlimBiome® in year one.
Stephen
O'Hara, CEO of OptiBiotix, commented: "Nouri is a well-known and respected brand in the
USA with an online presence and products in major retailers like
Walmart and Albertsons, the second largest supermarket in the USA.
This initial launch is for a FeelFull lemonade product with the
potential for further products within the FeelFull range depending
on sales progress. This launch represents a step forward for the
Company's products in the USA market and the first of a number of
launches planned with partners across the USA.
"With recent
product launches in India (Morepen, Amazon), China, large parts of
Asia (Philippines, Vietnam, Indonesia, Malysia and Thailand) and
now the USA, the Company is growing its brand presence in
international markets around the world. This global approach,
whilst taking longer than a single market approach but with greater
upside, has the potential to create multiple revenue streams and
build a substantial global business in the years ahead."
This announcement contains
information which, prior to its disclosure, was considered inside
information for the purposes of the UK Market Abuse Regulation and
the Directors of the Company are responsible for the release of
this announcement.
For further
information, please contact:
OptiBiotix Health plc
|
www.optibiotix.com
|
Neil Davidson, Chairman
|
Contact via Walbrook below
|
Stephen O'Hara, Chief
Executive
|
|
|
|
Cairn Financial Advisers LLP (NOMAD)
|
Tel: 020 7213 0880
|
Liam Murray / Ludovico
Lazzaretti
|
|
|
|
Peterhouse Capital Limited (Broker)
|
Tel: 020 7220 9797
|
Duncan Vasey / Lucy
Williams
|
|
|
|
Walbrook PR Ltd
|
Mob: 07876 741 001
|
Anna Dunphy
|
|
|
| |
About OptiBiotix - www.optibiotix.com
OptiBiotix Health plc (AIM: OPTI),
which was formed in March 2012, brings science to the development
of compounds which modify the human microbiome - the collective
genome of the microbes in the body - in order to prevent and manage
human disease and promote wellness.
OptiBiotix has an extensive R&D
programme working with leading academics in the development of
microbial strains, compounds, and formulations which are used as
active ingredients and supplements. More than twenty international
food and healthcare supplement companies have signed agreements
with OptiBiotix to incorporate their human microbiome modulators
into a wide range of food products and drinks.
OptiBiotix is also developing its own
range of consumer supplements and health products. The Company's
current areas of focus include obesity, cardiovascular health, and
diabetes.
Forward-Looking
Statements
Certain statements made in this
announcement are forward-looking statements. These forward-looking
statements are not historical facts but rather are based on the
Company's current expectations, estimates, and projections about
its industry; its beliefs; and assumptions. Words such as
'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,'
'estimates,' and similar expressions are intended to identify
forward-looking statements. These statements are not guarantees of
future performance and are subject to known and unknown risks,
uncertainties, and other factors, some of which are beyond the
Company's control, are difficult to predict, and could cause actual
results to differ materially from those expressed or forecasted in
the forward-looking statements. The Company cautions security
holders and prospective security holders not to place undue
reliance on these forward-looking statements, which reflect the
view of the Company only as of the date of this announcement. The
forward-looking statements made in this announcement relate only to
events as of the date on which the statements are made. The Company
will not undertake any obligation to release publicly any revisions
or updates to these forward-looking statements to reflect events,
circumstances, or unanticipated events occurring after the date of
this announcement except as required by law or by any appropriate
regulatory authority.